|
|||||
|
|
High-dose 131I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan |
|
| Authors: | Kayano Daiki Wakabayashi Hiroshi Nakajima Kenichi Kuroda Rie Watanabe Satoru Inaki Anri Toratani Ayane Akatani Norihito Yamase Takafumi Kunita Yuji Hiromasa Tomo Takata Aki Mori Hiroshi Saito Shintaro Araki Raita Taki Junichi Kinuya Seigo |
| Institution: | 1.Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan ;2.Department of Functional Imaging and Artificial Intelligence, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan ;3.Department of Pediatrics, Kanazawa University Hospital and Department of Pediatrics, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan ;4.Department of Radiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa, 920-0293, Japan ;5.Department of Pediatrics, Ishikawa Prefectural Central Hospital, 2-1 Kuratsuki-Higashi, Kanazawa, Ishikawa, 920-8530, Japan ; |
| Abstract: | Annals of Nuclear Medicine - The aim of the study was to investigate the outcomes and prognostic factors of high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy in patients with refractory or... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |